Heat Biologics Inc (NASDAQ:HTBX)’s stock price was down 7.4% on Monday . The stock traded as low as $0.24 and last traded at $0.25, approximately 2,585,100 shares traded hands during mid-day trading. An increase of 55% from the average daily volume of 1,672,908 shares. The stock had previously closed at $0.27.
Several equities analysts have weighed in on HTBX shares. ValuEngine lowered Heat Biologics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 4th. Maxim Group started coverage on Heat Biologics in a research note on Thursday, February 6th. They issued a “buy” rating on the stock.
The firm has a 50 day simple moving average of $0.31 and a two-hundred day simple moving average of $0.44. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.29 and a quick ratio of 3.29. The stock has a market cap of $15.36 million, a price-to-earnings ratio of -0.39 and a beta of 2.06.
A number of large investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new stake in shares of Heat Biologics during the fourth quarter worth about $28,000. Vanguard Group Inc. raised its position in shares of Heat Biologics by 6.8% during the second quarter. Vanguard Group Inc. now owns 1,327,660 shares of the biopharmaceutical company’s stock worth $909,000 after purchasing an additional 84,400 shares during the period. Finally, Renaissance Technologies LLC raised its position in shares of Heat Biologics by 69.8% during the fourth quarter. Renaissance Technologies LLC now owns 473,562 shares of the biopharmaceutical company’s stock worth $225,000 after purchasing an additional 194,654 shares during the period. 3.38% of the stock is currently owned by hedge funds and other institutional investors.
About Heat Biologics (NASDAQ:HTBX)
Heat Biologics, Inc, a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient’s immune system against cancer in the United States. The company’s T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness.
